Alto Neuroscience ANRO Business Segments — Stock-Based Comp

Similar metrics at other companies

CRDOReportable Segment — Stock-Based Comp

$50.76M+84.6%

SMMTReportable Segment — Stock-Based Comp

$72.79M+556%

QXOReportable Segment — Stock-Based Comp

$39.2M+94.1%

PRGSReportable Segment — Stock-Based Comp

$20.51M+22.5%

MDGLReportable Segment — Stock-Based Comp

$28.38M+43.3%

LFCRReportable Segment — Stock-Based Comp

$2.09M—

FAQ

What is Alto Neuroscience's business segments — stock-based comp?

Alto Neuroscience (ANRO) reported business segments — stock-based comp of $2.82M in Q1 2026.

How has Alto Neuroscience's business segments — stock-based comp changed year-over-year?

Alto Neuroscience's business segments — stock-based comp increased by 43.5% year-over-year, from $1.97M to $2.82M.

What is the long-term trend for Alto Neuroscience's business segments — stock-based comp?

Over 2 years (2023 to 2025), Alto Neuroscience's business segments — stock-based comp has grown at a 67.5% compound annual growth rate (CAGR), from $2.89M to $8.11M.

What does business segments — stock-based comp mean?

This metric captures the non-cash expense recognized for equity-based awards granted to employees and directors within the reportable segment. It reflects the cost of aligning management and staff incentives with long-term shareholder value through stock options or restricted stock units. Analyzing this expense is critical for understanding the dilutive impact on shareholders and the total cost of talent acquisition.